Text Size
Decrease TextReset TextIncrease Text

The Singapore Translational & Clinical Research in Psychosis (STCRP)

Translational and Clinical Research in Neuroscience vulnerability, disease progression, and treatment in Schizophrenia and related psychoses

Schizophrenia and related psychoses are amongst the most disabling and most costly of all disorders to afflict mankind. Despite the low lifetime prevalence of psychoses, estimated to be about 3% worldwide, it generates an enormous burden in both economic cost and human suffering. The exact aetiology and pathophysiology are yet to be elucidated but research has advanced recently in three directions: the identification of genetic risk factors, the identification of those at greatest risk for the disorder, and a focus on the development of new treatments that may reduce disability.

IMH has embarked on a bench-to-bedside research programme focusing on the three areas. The overall objective is to identify key genetic, biological, cognitive and social risk factors for psychotic disorders, and to establish the efficacy of a new neurocognitive enhancing agent in patients with schizophrenia.

This programme will focus on the following three interlinked projects:

  • A Comprehensive Genetic Study of Schizophrenia and Neurocognitive Impairments
  • Prospective Observational Study of Young Adults at Ultra High Risk for Psychotic Disorders; and
  • Double-blind randomized controlled trial of cognitive enhancement.

The team led by A/Prof Chong Siow Ann includes internationally recognized researchers from various institutions in Singapore as well as from Duke University and the University of Melbourne.

They encompass a broad range of expertise, from basic science (in genomics, neuroimaging) to clinical acumen regarding high-risk psychosis studies and assessment and treatment of cognitive deficits in schizophrenia.

An extensive network of collaboration has been set up with the Genome Institute of Singapore, Singapore Clinical Research Institute, National University of Singapore, University of Melbourne, and Duke University, encompassing various aspects of early detection, epidemiology, genetics and treatment. It will also involve research and academic centres in Hong Kong, New York and Shanghai.

This five-year 25-million dollar (SGD) program is funded by the National Medical Research Council (NMRC), Singapore.

Principal Investigator:

  • A/Prof Chong Siow Ann, Institute of Mental Health

Co-Principal Investigators:

  • A/Prof Liu JianJun, Genome Institute of Singapore
  • Prof Richard Keefe, Duke University Medical Center
  • A/Prof Christine Marx, Duke University Medical Center
  • Prof Patrick McGorry, University of Melbourne

Click here to read about our achievements.

A member of National Healthcare Group ISO   Comm Chest Award Bronze